Clinical Trial Update: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing venetoclax plus obinutuzumab against FCR/BR in previously untreated chronic lymphocytic leukemia has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Status: COMPLETED | Results posted: 2025-04-17